Free Trial

Eyepoint Pharmaceuticals (EYPT) Competitors

Eyepoint Pharmaceuticals logo
$11.55 -0.18 (-1.53%)
Closing price 10/16/2025 04:00 PM Eastern
Extended Trading
$11.70 +0.15 (+1.34%)
As of 10/16/2025 06:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

EYPT vs. TXG, ALNT, AEHR, TRNS, CTKB, LAB, FEIM, SENS, QSI, and MASS

Should you be buying Eyepoint Pharmaceuticals stock or one of its competitors? The main competitors of Eyepoint Pharmaceuticals include 10x Genomics (TXG), Allient (ALNT), Aehr Test Systems (AEHR), Transcat (TRNS), Cytek Biosciences (CTKB), Standard BioTools (LAB), Frequency Electronics (FEIM), Senseonics (SENS), Quantum-Si (QSI), and 908 Devices (MASS). These companies are all part of the "measuring and control equipment" industry.

Eyepoint Pharmaceuticals vs. Its Competitors

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and 10x Genomics (NASDAQ:TXG) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. Comparatively, 84.7% of 10x Genomics shares are held by institutional investors. 4.5% of Eyepoint Pharmaceuticals shares are held by company insiders. Comparatively, 9.4% of 10x Genomics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Eyepoint Pharmaceuticals has a beta of 1.95, suggesting that its share price is 95% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 2.05, suggesting that its share price is 105% more volatile than the S&P 500.

10x Genomics has a net margin of -13.13% compared to Eyepoint Pharmaceuticals' net margin of -337.93%. 10x Genomics' return on equity of -12.88% beat Eyepoint Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Eyepoint Pharmaceuticals-337.93% -63.80% -50.72%
10x Genomics -13.13%-12.88%-10.03%

Eyepoint Pharmaceuticals has higher earnings, but lower revenue than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eyepoint Pharmaceuticals$43.27M18.40-$130.87M-$2.68-4.31
10x Genomics$610.78M2.52-$182.63M-$0.70-17.69

Eyepoint Pharmaceuticals presently has a consensus target price of $28.33, indicating a potential upside of 145.31%. 10x Genomics has a consensus target price of $13.65, indicating a potential upside of 10.29%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Eyepoint Pharmaceuticals is more favorable than 10x Genomics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eyepoint Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71
10x Genomics
2 Sell rating(s)
7 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.38

In the previous week, 10x Genomics had 5 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 19 mentions for 10x Genomics and 14 mentions for Eyepoint Pharmaceuticals. 10x Genomics' average media sentiment score of 0.68 beat Eyepoint Pharmaceuticals' score of 0.51 indicating that 10x Genomics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Eyepoint Pharmaceuticals
3 Very Positive mention(s)
3 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
10x Genomics
3 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

10x Genomics beats Eyepoint Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Eyepoint Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EYPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EYPT vs. The Competition

MetricEyepoint PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$808.52M$3.41B$6.09B$10.55B
Dividend YieldN/A2.29%5.73%4.78%
P/E Ratio-4.3122.9385.0727.19
Price / Sales18.40486.15604.99132.96
Price / CashN/A46.9737.8662.13
Price / Book2.3410.5012.396.65
Net Income-$130.87M-$52.47M$3.32B$276.79M
7 Day Performance-14.89%2.90%2.30%1.75%
1 Month Performance-15.32%15.36%9.67%5.15%
1 Year Performance3.59%14.29%73.80%36.96%

Eyepoint Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EYPT
Eyepoint Pharmaceuticals
2.3941 of 5 stars
$11.55
-1.5%
$28.33
+145.3%
+2.4%$808.52M$43.27M-4.31120News Coverage
TXG
10x Genomics
4.0556 of 5 stars
$11.60
+1.1%
$13.65
+17.7%
-21.3%$1.43B$610.78M-16.571,240Trending News
Analyst Forecast
Analyst Revision
ALNT
Allient
2.6862 of 5 stars
$48.25
+5.1%
$35.00
-27.5%
+160.0%$778.04M$529.97M56.102,525
AEHR
Aehr Test Systems
1.9968 of 5 stars
$25.52
+8.6%
$24.00
-6.0%
+87.8%$704.85M$58.97M-116.0090
TRNS
Transcat
3.6689 of 5 stars
$69.86
+2.0%
$112.20
+60.6%
-45.7%$638.31M$278.42M48.851,245Positive News
CTKB
Cytek Biosciences
1.8373 of 5 stars
$3.96
+2.9%
$5.60
+41.4%
-25.0%$489.81M$200.45M-79.20500
LAB
Standard BioTools
2.6189 of 5 stars
$1.29
+0.8%
$1.55
+20.2%
-31.7%$488.95M$174.43M-4.03620News Coverage
FEIM
Frequency Electronics
2.7938 of 5 stars
$37.44
+5.4%
$43.00
+14.9%
+179.1%$346.29M$69.81M16.35200
SENS
Senseonics
1.9092 of 5 stars
$0.42
-0.2%
$1.54
+266.8%
+21.5%$341.51M$25.47M-3.2290
QSI
Quantum-Si
2.5778 of 5 stars
$2.08
+24.6%
$3.48
+67.1%
+211.1%$338.17M$3.06M-3.06150Options Volume
Gap Up
High Trading Volume
MASS
908 Devices
1.3338 of 5 stars
$7.87
-1.6%
$8.00
+1.7%
+145.9%$286.89M$59.63M-14.5760News Coverage
Analyst Revision

Related Companies and Tools


This page (NASDAQ:EYPT) was last updated on 10/17/2025 by MarketBeat.com Staff
From Our Partners